<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466711</url>
  </required_header>
  <id_info>
    <org_study_id>RM-131-010</org_study_id>
    <nct_id>NCT02466711</nct_id>
  </id_info>
  <brief_title>Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers</brief_title>
  <official_title>A Single-center, Placebo-controlled, Double-blind Study to Evaluate the Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Motus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Motus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of relamorelin (RM-131) on gastric&#xD;
      volume, motor and sensory effects in healthy patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric volume measured by single photon emission computed tomography (SPECT)</measure>
    <time_frame>Measured during the 1 hour study procedure</time_frame>
    <description>Calculation of gastric volume by single photon emission computed tomography (SPECT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satiety measured by the Hunger/Satiety questionnaire</measure>
    <time_frame>Measured during a 1 hour study procedure</time_frame>
    <description>Measurement of satiety by completion of the Hunger/Satiety questionnaire after ingesting a nutrient drink</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric motility measured by gastroduodenal manometry</measure>
    <time_frame>Measured during the 4 hour study procedure</time_frame>
    <description>Measurement of gastric motility by gastroduodenal manometry</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Gastric Motility</condition>
  <arm_group>
    <arm_group_label>Relamorelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relamorelin</intervention_name>
    <description>Double blind RM-131 will be delivered three times by injection during the course of the study</description>
    <arm_group_label>Relamorelin</arm_group_label>
    <other_name>RM-131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double blind Placebo will be delivered three times by injection during the course of the study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide written informed consent prior to any study procedures, and be willing&#xD;
             and able to comply with study procedures&#xD;
&#xD;
          2. No medical problems or chronic diseases, specifically, no type 2 diabetes mellitus&#xD;
&#xD;
          3. Body mass index of 18-35 kg/mÂ²&#xD;
&#xD;
          4. Female subjects must have negative urine pregnancy tests and must not be lactating&#xD;
             prior to receiving study medication and radiation exposure. For females able to bear&#xD;
             children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier&#xD;
             method, or a double-barrier method of birth control must be used throughout the study.&#xD;
             Female subjects unable to bear children must have this documented in the medical&#xD;
             record (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum&#xD;
             of one year since the last menstrual period]).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable or unwilling to provide informed consent or to comply with study procedures&#xD;
&#xD;
          2. Diagnosis of gastrointestinal diseases&#xD;
&#xD;
          3. Structural or metabolic diseases that affect the GI system&#xD;
&#xD;
          4. Unable to avoid the following over- the- counter medications 48 hours prior to the&#xD;
             baseline period and throughout the study:&#xD;
&#xD;
               1. Medications that alter GI transit including laxatives, magnesium and aluminum&#xD;
                  containing antacids, prokinetics, erythromycin,&#xD;
&#xD;
               2. Analgesic drugs including NSAIDs and COX-2 inhibitors NOTE: stable doses of&#xD;
                  thyroid replacement, estrogen replacement, low-dose aspirin for cardioprotection,&#xD;
                  and birth control (but with adequate backup contraception as drug-interactions&#xD;
                  with birth control have not been conducted) are permissible.&#xD;
&#xD;
          5. History of recent surgery (within 60 days of screening)&#xD;
&#xD;
          6. Acute or chronic illness or history of illness, which in the opinion of the&#xD;
             Investigator, could pose a threat or harm to the subject or obscure interpretation of&#xD;
             laboratory test results or interpretation of study data such as frequent angina, Class&#xD;
             III or IV congestive heart failure, moderate impairment of renal or hepatic function,&#xD;
             poorly controlled diabetes, etc.&#xD;
&#xD;
          7. Any clinically significant abnormalities on physical examination or laboratory&#xD;
             abnormalities identified in the medical record, as determined by the Investigator&#xD;
&#xD;
          8. Acute GI illness within 48 hours of initiation of the baseline period&#xD;
&#xD;
          9. Females who are pregnant or breastfeeding&#xD;
&#xD;
         10. History of excessive alcohol use or substance abuse&#xD;
&#xD;
         11. Participation in an investigational study within the 30 days prior to dosing in the&#xD;
             present study&#xD;
&#xD;
         12. Any other reason, which in the opinion of the Investigator, would confound proper&#xD;
             interpretation of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric motility</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

